PAD1 Monoclonal Antibody (Clone

Confirm delete?

PAD1 Monoclonal Antibody (Clone 6B4)

Zoom

Cat No: 22997

Protein arginine deiminases (PADs) are guanidine-modifying enzymes belonging to the amidinotransferase superfamily and are designated PAD1-4, and PAD6. PADs are calcium-dependent enzymes that catalyze the post-translational modification of target prot...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Correlated keywords:

PADI-1 mab PDI PAD-2 3 4 6 PTM

Product Overview:
Protein arginine deiminases (PADs) are guanidine-modifying enzymes belonging to the amidinotransferase superfamily and are designated PAD1-4, and PAD6. PADs are calcium-dependent enzymes that catalyze the post-translational modification of target proteins by converting arginine to citrulline.{19489, 18141} The excess deimination of target proteins can result in the production of anti-citrullinated protein antibodies (ACPAs) which can be indicators of a number of disease states.{31883} The various PADs exhibit tissue specific expression and different subcellular localization.{19488} PAD1 is expressed in uterus and throughout the epidermis. PAD1 and PAD3 are speculated to mediate deamination of epidermal filaggrin (filament aggregation protein) and keratins, proteins involved in maintaining skin hydration.{19490} The predicted size for PAD1 is 74.7 kD and Cayman’s PAD1 monoclonal antibody (clone 6B4) detects a band at ~74 kD by Western blot.

Size	100 µg
Shipping	dry ice
Host	Mouse
Antigen	Recombinant human PAD1 protein
Clone	6B4
Isotype	IgG2b
Application(s)	ELISA and WB
Formulation	100 µg of protein G-purified antibody
Custom Code	3822.19
UNSPSC code	12352203

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.